Editor’s Note: this is Part 2 of our Real World Evidence blog series. To view Part 1, please click here.
A large pharmaceutical company sought to better understand the costs and outcomes associated with different pathways of Crohn’s Disease treatment by analyzing Real World Evidence. The company had faced a number of challenges in performing these analyses in the past. Continue reading RWE Part 2: Case Study – Performing Treatment Pathway Analyses Using Real World Evidence